$100M Stock Offering Fuels Alto Neuroscience’s Depression Drug Push
Event summary
- $100M offering priced at $26.48/share, closing July 14, 2026.
- Proceeds to accelerate Phase 3 trial for ALTO-207 in treatment-resistant depression.
- EcoR1 Capital led financing with new and existing healthcare investors.
- Joint book-running managers: BofA Securities, Stifel, William Blair, Baird.
The big picture
Alto’s $100M raise underscores the high-stakes race to develop better treatments for treatment-resistant depression, a market with significant unmet need. The financing comes as biotech investors increasingly prioritize clinical-stage assets with clear differentiation potential in neuroscience. Alto’s ability to leverage its Precision Psychiatry Platform could set it apart, but competition remains fierce.
What we're watching
- Clinical Execution
- Whether Alto can deliver Phase 3 results for ALTO-207 on an accelerated timeline.
- Investor Confidence
- How new investor participation impacts valuation and market perception.
- Competitive Positioning
- The pace at which Alto advances its pipeline relative to peers in treatment-resistant depression.